Related Experiment Video
Updated: Nov 3, 2025
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
PARP inhibition in UV-associated angiosarcoma preclinical models
Marije E Weidema1, Ingrid M E Desar2, Melissa H S Hillebrandt-Roeffen2
1Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. Marije.Weidema@radboudumc.nl.
Combination therapy with olaparib and temozolomide shows promise for UV-induced angiosarcoma (AS). This treatment is synergistic, increasing apoptosis and DNA damage in UV AS cell lines, suggesting a potential new therapeutic option for this rare cancer.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Angiosarcoma (AS) is a rare, aggressive vascular sarcoma with poor survival rates.
- Subtypes like UV-induced AS (UV AS) may be susceptible to DNA damage repair inhibition.
- Novel treatment strategies are urgently needed for AS patients.
Purpose of the Study:
- To investigate the expression of poly(ADP-ribose)polymerase-1 (PARP1) and Schlafen-11 (SLFN11) biomarkers in UV AS.
- To evaluate the efficacy of combining a PARP inhibitor (olaparib) with temozolomide (TMZ) in UV AS cell lines.
- To explore the potential of this combination as a subtype-specific treatment for UV AS.
Main Methods:
- Immunohistochemical analysis of PARP1 and SLFN11 expression in UV AS and non-UV AS patient samples.
- In vitro treatment of two UV AS cell lines (MO-LAS, AS-M) with olaparib and TMZ, individually and in combination.
- Assessment of cell viability, treatment synergy, apoptosis, and DNA damage (γH2AX).
Main Results:
- PARP1 was expressed in 98% of UV AS samples, and SLFN11 in 80%.
- Combination treatment with olaparib and TMZ demonstrated synergy in both UV AS cell lines.
- The combination significantly increased apoptosis and DNA damage (γH2AX) compared to single agents.
Conclusions:
- The combination of olaparib and TMZ is synergistic in UV AS cell lines.
- PARP1 and SLFN11 are frequently expressed in UV AS tumors.
- This combination therapy represents a potential novel, subtype-specific treatment for UV AS.
